+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Skin Cancer Drugs Market Research Reports

From
From
BRAF-Mutant Metastatic Melanoma - Epidemiology Forecast to 2032 - Product Thumbnail Image

BRAF-Mutant Metastatic Melanoma - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Gorlin Syndrome - Epidemiology Forecast to 2032 - Product Thumbnail Image

Gorlin Syndrome - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Basal Cell Neoplasms - Epidemiology Forecast to 2032 - Product Thumbnail Image

Basal Cell Neoplasms - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Metastatic Cutaneous Melanoma - Epidemiology Forecast - 2032 - Product Thumbnail Image

Metastatic Cutaneous Melanoma - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
From
Actinic Keratosis - Epidemiology Forecast - 2032 - Product Thumbnail Image

Actinic Keratosis - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Nonmelanoma Skin Cancer- Epidemiology Forecast to 2032 - Product Thumbnail Image

Nonmelanoma Skin Cancer- Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Refractory Metastatic Melanoma - Epidemiology Forecast to 2032 - Product Thumbnail Image

Refractory Metastatic Melanoma - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Basal Cell Nevus Syndrome - Epidemiology Forecast - 2032 - Product Thumbnail Image

Basal Cell Nevus Syndrome - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Malignant Melanoma - Epidemiology Forecast to 2032 - Product Thumbnail Image

Malignant Melanoma - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Melanoma - Epidemiology Forecast to 2032 - Product Thumbnail Image

Melanoma - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Merkel Cell Carcinoma - Epidemiology Forecast to 2032 - Product Thumbnail Image

Merkel Cell Carcinoma - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Metastatic Melanoma - Epidemiology Forecast to 2032 - Product Thumbnail Image

Metastatic Melanoma - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Metastatic Uveal Melanoma (MUM) - Epidemiology Forecast to 2032 - Product Thumbnail Image

Metastatic Uveal Melanoma (MUM) - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Nexavar (Sorafenib) - Drug Insight and Market Forecast - 2030 - Product Thumbnail Image

Nexavar (Sorafenib) - Drug Insight and Market Forecast - 2030

  • Report
  • August 2020
  • 80 Pages
  • Global
From
Loading Indicator

The Skin Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat skin cancer. These drugs are used to treat a variety of skin cancer types, including melanoma, basal cell carcinoma, and squamous cell carcinoma. The drugs are typically administered orally, intravenously, or topically. The market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include Bristol-Myers Squibb, Merck & Co., Novartis, Pfizer, and Roche. These companies are constantly researching and developing new treatments to improve the efficacy of existing treatments and to develop new treatments for skin cancer. In addition to the major players, there are also many smaller companies that are developing treatments for skin cancer. These companies are often focused on developing treatments for rarer forms of skin cancer, such as Merkel cell carcinoma. Examples of these companies include Aduro Biotech, Arcutis Biotherapeutics, and OncoSec Medical. Show Less Read more